Heukelbach Jörg, Wilcke Thomas, Winter Benedikt, Sales de Oliveira Fabíola Araújo, Sabóia Moura Rômulo César, Harms Gundel, Liesenfeld Oliver, Feldmeier Hermann
Department of Community Health, Federal University of Ceará State, Fortaleza CE Brazil.
Arzneimittelforschung. 2004;54(7):416-21. doi: 10.1055/s-0031-1296993.
Ivermectin (CAS 70288-86-7) is a potent antiparasitic drug. However, studies have not been published evaluating the efficacy of ivermectin in a patient population concomitantly infected with intestinal helminths and ectoparasites. Here the results of an open trial on the efficacy of ivermectin in a heavily poly-parasitized population in northeast Brazil are presented. Two hundred and fifty-one patients were enrolled. Two doses of ivermectin (200 microg/kg) were given at an interval of 10 days. The cure rates for intestinal helminthiases were: 100% for strongyloidiasis and enterobiasis, 99% for ascariasis, 84% for trichuriasis, 68% for hookworm disease, and 50% for hymenolepiasis. Cure rates for ectoparasitoses were: 100% for cutaneous larva migrans, 99% for pediculosis, 88% for scabies and 64% for tungiasis. The results show that two doses of ivermectin are highly efficacious for most intestinal helminths and ectoparasites simultaneously present in an impoverished population. The drug seems to be particularly useful when polyparasitism is expected to occur or when public health measures aim to reduce both intestinal helminthiases and parasitic skin diseases by mass chemotherapy.
伊维菌素（CAS 70288-86-7）是一种强效抗寄生虫药物。然而，尚未发表关于伊维菌素在同时感染肠道蠕虫和外寄生虫的患者群体中的疗效评估研究。本文介绍了在巴西东北部寄生虫感染严重的人群中进行的一项关于伊维菌素疗效的开放试验结果。共纳入251名患者。给予两剂伊维菌素（200微克/千克），间隔10天。肠道蠕虫病的治愈率分别为：粪类圆线虫病和蛲虫病为100%，蛔虫病为99%，鞭虫病为84%，钩虫病为68%，微小膜壳绦虫病为50%。外寄生虫病的治愈率分别为：皮肤幼虫移行症为100%，虱病为99%，疥疮为88%，潜蚤病为64%。结果表明，两剂伊维菌素对贫困人群中同时存在的大多数肠道蠕虫和外寄生虫具有高效。当预计会发生多重寄生虫感染或公共卫生措施旨在通过群体化疗减少肠道蠕虫病和寄生虫性皮肤病时，该药物似乎特别有用。
Zotero 插件